Featured
The End of the Biotech Gold Rush: How AI Validation, GLP-1 Sarcopenia, and Diagnostic Bottlenecks Are Rewriting Medical Research
The convergence of Phase 3 mRNA oncology data, FDA AI guidance, and GLP-1 metabolic outcomes marks the end of biotech's discovery phase. This analysis...
Read Full Story →